The authors confirmed the osteogenic effect in vivo, reporting decreased s-sclerostin levels, and increased BMD and s-OC levels in T2DM OLEFT rats treated with the antidiabetic medication (116). This evidence concerns the gene SOST and type 2 diabetes mellitus.